Navigation Links
Business of drug development on verge of great change

Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping transform the business of drug research and development.

According to Christopher Austin, M.D., director of the NIH Chemical Genomics Center (NCGC), both industry and academia welcome more cooperation in drug discovery to secure more efficient results for less financial burden than if they operate independently. The increased participation of the public sector in therapeutics development is a trend that will be good for industry, academia, scientific discovery and the public at large, says Dr. Austin.

These collaborative efforts have been facilitated by researchers moving from industry to academia to help close the gap that exists between basic early stage research and the identification of viable drug candidates for a range of diseases, particularly those that are less prevalent or for which the targets are less well validated. The hope is that better drugs to treat more diseases will be developed faster and less expensively than ever before.

Not only is Dr. Austin a scientist who wants his work to improve the lives of people affected by disease, he also is a former pharmaceutical industry researcher who understands the business of drug development, having previously worked at Merck & Co. for a number of years. Hes observed that industry scientists are constrained in the scope of targets and diseases they study by commercial regulations imperatives which do not exist in the public sector. The work we do at the NCGC is complementary to what industry does we work on the 90% of new targets and diseases that industry doesnt, and we make our data publicly available so all researchers, public and private, can use it to advance drug discovery.

Marcie Glicksman, Ph.D., senior director of lead discovery, laboratory of drug discovery at the Harvard NeuroDiscovery Center and one of several co-presenters at the SBS meeting, also came from industry and has high hopes for the increased collaboration between Big Pharma and academia in drug discovery. At Harvard, our mission is to develop new therapeutics for diseases with no disease modifying treatments such as Parkinsons and Alzheimers, or orphan diseases such as Huntingtons and Amyotrophic Lateral Sclerosis (Lou Gehrigs), she states. There are smaller numbers of patients affected by orphan diseases -- treatments for them are not considered billion dollar drugs, so they are much harder to develop in industry.

Like Dr. Austin, Dr. Glicksman says its simply too expensive for industry to conduct this early stage research, and that is why the academic centers are so vital to the future of drug discovery for diseases that industry cant address on its own.

Dr. Austin and Dr. Glicksman will speak at a session on this topic at the 14th Annual Conference & Exhibition of the Society for Biomolecular Sciences (SBS) April 6-10 at Americas Center in St. Louis.


Contact: Jennifer Bender
203-325-8772 x18
Society for Biomolecular Sciences

Related medicine news :

1. Underwriters Laboratories Management System Registration Business to Merge With Germanys DQS
2. Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum
3. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
6. Barr Announces Reorganization of Senior Management, Business Functions
7. Small Business Health Care Survey Points to Need for Reform
8. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
9. Adds Vice President of Business Development
10. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
11. Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc.
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... Etymotic Research, manufacturer of ... of Companion Mics, the CM•4 Multi-Talker Noise Reduction System, as well as its ... Acousticians’ (EUHA) 60th Annual Congress in Nuremberg, Germany. , The conference and ...
(Date:10/12/2015)... ... , ... On July 22nd four military veterans departed the headwaters of the ... river to the Gulf of Mexico. Their mode of transportation: Old Town NEXT canoes. ... remaining for a November 22nd arrival at the gulf. , The excursion was developed ...
(Date:10/12/2015)... Coeur d'Alene, ID (PRWEB) , ... October 12, ... ... opportunity for organizations to be a part of a contact channel benchmarking ... valuable insights and comparisons of key operational strategies for improving customer experience, customer ...
(Date:10/12/2015)... , ... October 12, 2015 , ... NFL football fans who are interested in having ... a great cause. CLICK HERE to donate to Smile for a Lifetime (S4L) ... to win an all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law ... a contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported ... of its ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... , Oct. 12 2015 ... the addition of the "Personalized Medicine, ... 2019 - Strategic Analysis of Industry Trends, ... their offering. --> ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ...
(Date:10/12/2015)... -- To help address the growing opioid epidemic in the ... Board of Directors is calling for a comprehensive ... the tracking of opioid prescription use; research funding for ... abuse treatment programs. David Ring , MD, ... "The new , AAOS Information Statement on Opioid Use, ...
(Date:10/12/2015)... Minn. , Oct. 12, 2015 Device ... a need to help integrate these devices into existing ... of ergonomic healthcare mounting and mobility solutions, has launched ... lightest cart yet, for a wide array of laptops ... Cart SV10 was developed exclusively for Microsoft Surface and ...
Breaking Medicine Technology: